Distal Subungual Onychomycosis
Conditions
Brief summary
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Detailed description
Male or female subjects aged between 12 and 75 years with confirmed DSO involving 20-60% of at least one great toenail will be screened for randomization in this study. The diagnosis of DSO will be confirmed prior to randomization through a positive culture of dermatophytes. In addition, a central blinded assessment of the clinical disease involvement (i.e., affected nail area) will be performed at Screening. Subjects have to meet all eligibility criteria before being randomized in to the study. Eligible subjects will be randomized to the investigational medicinal products (MOB015B or vehicle) in a ratio of 2:1. The investigational medicinal products (IMPs) will be applied to all affected fingernails and/or toenails for 48 weeks once daily at bedtime. However, fingernails will not be assessed for efficacy. Since both the IMPs are indistinguishable in appearance and mode of administration, the study will be performed as a double-blind study, i.e., both the investigator and the subject will remain blinded throughout the entire study. After a 4-week follow-up period without IMP treatment the end of study (EoS) Visit will be performed at Week 52 (Visit 7). The primary efficacy variable will be assessed at Week 52. The end of the clinical study for each individual subject is defined as the EoS Visit at Week 52 (Visit 7). The end of the clinical study is defined as the last visit of the last subject in the study.
Interventions
DRUGMOB015B
MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
DRUGMOB015B Vehicle
MOB015B Vehicle without the active ingredient Terbinafine
Sponsors
Moberg Pharma AB
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females 12 - 75 years of age 2. Distal subungual onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target nail 3. Positive culture for dermatophytes 4. Written informed consent
Exclusion criteria
1. Proximal subungual onychomycosis 2. Distal subungual onychomycosis of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm) 3. Target toenail thickness more than 3 mm 4. Spike of onychomycosis extending to eponychium of the target toenail 5. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail 6. Other conditions than DSO known to cause abnormal nail appearance 7. Presence of toenail infection other than dermatophytes 8. Previous target toenail surgery with any residual disfigurement 9. Topical treatment of the nails with other antifungal medication within 6 weeks before screening/Visit 1 10. Systemic use of antifungal treatment within 6 months before screening/visit 1 11. Severe moccasin tinea pedis 12. Signs of severe peripheral circulatory insufficiency 13. Uncontrolled diabetes mellitus 14. Known immunodeficiency 15. Participation in another clinical trial with an investigational drug or device during the previous 3 months before Baseline/ Visit 2 16. Known allergy to any of the tested treatment products 17. A positive pregnancy test at Baseline/Visit 2 indicating pregnancy in a woman of childbearing potential or a premenarche subject 18. Females who are pregnant or breastfeeding 19. Men who have female sexual partners of child-bearing potential and sexually active women of child-bearing potential who are not practicing an acceptable method of birth control, or who will not remain abstinent through the trial. 20. Patients previously randomized in this study 21. History of, or current drug or alcohol abuse 22. Psychiatric condition that might limit the participation in the study and/or that lead to the assumption that the patient's ability to completely understand the consequences of consent is missing 23. Close affiliation with the investigator (e.g. a close relative) or persons working at a study site, or patient who is an employee of the sponsor's company 24. Patients who are institutionalized because of legal or regulatory order 25. Any diseases or circumstances in which the patient should not participate in the study in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Subjects with complete cure of the target toe nail at Week 52 | Week 52 | Complete cure was defined as negative fungal culture of dermatophytes, negative direct potassium hydroxide (KOH) microscopy and 0% clinical disease involvement of the target toenail. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjects with mycological cure of the target toe nail at Week 52 | Week 52 | Mycological cure was defined as negative fungal culture of dermatophytes and negative direct KOH microscopy of the target toenail. |
| Subjects with treatment success of the target toe nail at Week 52 | Week 52 | Treatment success was defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and ≤10% clinical disease involvement of the target toenail. |
Countries
Canada, United States
Outcome results
None listed